BUSINESSJun 3 · 13:36 UTCSTAT NEWSElaine Chen

STAT+: Legend Biotech emerged as a rare market winner

Legend Biotech's shares surged over 40% following the disclosure of early positive data on its in vivo CAR-T therapy for Non-Hodgkin’s lymphoma, making it a rare market winner amid a broader biotech selloff.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Legend BiotechorganizationCAR-T therapytopicNon-Hodgkin’s lymphomatopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 14 · 14:14 UTC
STAT+: BeOne wins FDA approval in lymphoma race
BUSINESSApr 30 · 16:36 UTC
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
BUSINESSJan 24 · 16:52 UTC
Novo Nordisk Shares Surge on New Obesity Drug Results
BUSINESSApr 17 · 17:41 UTC
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
BUSINESSMay 4 · 10:45 UTC
Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
BUSINESSApr 18 · 13:30 UTC
Strong Earnings Results Can’t Save Stocks from Dimming Forecasts